BioSpace News Archive

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that John A. Hohneker, M.D., president and chief executive officer of Anokion, will present a company overview at the Cowen 40th Annual Healthcare Conference

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the publication in the peer-reviewed Journal of Neuroimmunology,

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2019 fourth quarter on Friday, February 28, 2020, after market close

GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the Cowen 40th Annual Healthcare Conference

Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 15/536,237, titled, “Phosphoramidates for the Treatment of Hepatitis B Virus,”

Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health and neuroendocrine disorders, today announced the initiation of a Phase 2 trial of SJX-653, a novel, potent, selective neurokinin 3 (NK3) antagonist in clinical development as a non-hormonal once-daily (QD) treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, commonly called hot flashes.

ReadCoor, Inc., a company leading true multi-omic spatial sequencing, today unveils its first product line, including multi-omic spatial sequencing assays and the RC2 instrument.

Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the publication of a multi-national study entitled “Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide‐Releasing Anti- Inflammatory Drug (ATB‐352): A Role for Endogenous Cannabinoids”.

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end 2019 financial results for the period ended December 31, 2019, on Monday, March 2, 2020, after the market closes.

Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it will provide a corporate overview and financial results for the quarter and year ended December 31, 2019 by hosting a conference